Opinion|Videos|October 4, 2024
Overview of Recent Updates in Bispecific Therapy in R/R MM
The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss similarities/differences in mechanism of action, key efficacy endpoints and safety data:
- Teclistamab
- MajesTEC-1 (NEJM 2022)
- MajesTEC-1 Long-term Follow-up (ASCO 2024)
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5